| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | TRT Catalog |
| URL | trtcatalog.com/learn/fda-testosterone-low-libido-idiopathic-hypogonadism (opens in a new tab) |
Specific Claim Evaluated
On April 16, 2026, the FDA announced it would accept supplemental NDAs for testosterone products to treat low libido in men with idiopathic hypogonadism, with a sponsor contact deadline of April 30, 2026.
Primary Research Supporting or Contradicting the Claim
The Federal Register notice invites holders of approved testosterone NDAs to contact the agency regarding a supplemental application for this indication (U.S. Food and Drug Administration, 2026a).
Corrected Evidence-Based Interpretation
Accurate. The announcement opens a pathway; it is not an approval.
Rationale for Grade
The page reports dates and scope correctly and distinguishes the pathway from an approved indication. It acknowledges that online clinics already prescribe off-label for low libido. Despite its commercial setting, the factual content matches the primary notice.
References
- U.S. Food and Drug Administration. Potential new indication for testosterone replacement therapy. Federal Register. 2026;91 FR 21002. Document 2026-07615. Published April 20, 2026.
Supporting excerpt: "information in published literature that seems promising"